GoAI
Get started
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc.

TCRX

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$0.7773

+$0.0033 · +0.43%

Aug 21, 3:55 PM ET

TCRX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

72

Undervalued

Momentum

45

Neutral

Sentiment

46

Mixed

Risk resilience

28

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Gavin MacBeath
Listed since
Jul 16, 2021
Employees
138

Market position

Volume
136.16K
0.19× average
Average volume
699.75K
Average daily volume
Market cap
47.61M USD
Beta
1.07
Market reference 1

Financials

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends589%-1366%-3321%-5276%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 72.24%Operating margin, FY2021: -479.65%Operating margin, FY2022: -492.32%Operating margin, FY2023: -444.00%Operating margin, FY2024: -4787.68%Operating margin, FY2025: -1315.38%Net margin, FY2021: -479.49%Net margin, FY2022: -489.26%Net margin, FY2023: -423.86%Net margin, FY2024: -4527.66%Net margin, FY2025: -1256.81%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 72.24%. Operating margin FY2021 -479.65%. Operating margin FY2022 -492.32%. Operating margin FY2023 -444.00%. Operating margin FY2024 -4787.68%. Operating margin FY2025 -1315.38%. Net margin FY2021 -479.49%. Net margin FY2022 -489.26%. Net margin FY2023 -423.86%. Net margin FY2024 -4527.66%. Net margin FY2025 -1256.81%.

Income trends

Revenue

10.33M USD+266.65%

Operating income

−135.81M USD-0.74%

Net income

−129.77M USD-1.78%
Income trends across reported periods36.74M USD−26.01M USD−88.75M USD−151.5M USDRevenue, FY2021: 10.14M USDRevenue, FY2022: 13.54M USDRevenue, FY2023: 21.05M USDRevenue, FY2024: 2.82M USDRevenue, FY2025: 10.33M USDOperating income, FY2021: −48.64M USDOperating income, FY2022: −66.64M USDOperating income, FY2023: −93.46M USDOperating income, FY2024: −134.82M USDOperating income, FY2025: −135.81M USDNet income, FY2021: −48.63M USDNet income, FY2022: −66.22M USDNet income, FY2023: −89.22M USDNet income, FY2024: −127.5M USDNet income, FY2025: −129.77M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 10.14M USD. Revenue FY2022 13.54M USD. Revenue FY2023 21.05M USD. Revenue FY2024 2.82M USD. Revenue FY2025 10.33M USD. Operating income FY2021 −48.64M USD. Operating income FY2022 −66.64M USD. Operating income FY2023 −93.46M USD. Operating income FY2024 −134.82M USD. Operating income FY2025 −135.81M USD. Net income FY2021 −48.63M USD. Net income FY2022 −66.22M USD. Net income FY2023 −89.22M USD. Net income FY2024 −127.5M USD. Net income FY2025 −129.77M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue10.33M USD2.82M USD21.05M USD13.54M USD10.14M USD
Cost of goods sold2.87M USD————
Gross profit7.46M USD2.82M USD21.05M USD13.54M USD10.14M USD
Research and development114.15M USD107.35M USD88.15M USD59.82M USD44.95M USD
Selling, general, and administrative31.99M USD29.56M USD25.49M USD20.35M USD13.83M USD
Operating expenses143.27M USD137.64M USD114.51M USD80.17M USD58.78M USD
Interest income8.82M USD12.07M USD8M USD1.59M USD16K USD
Interest expense2.77M USD3.65M USD3.76M USD1.18M USD—
Depreciation and amortization2.87M USD4.11M USD5.36M USD5.14M USD3.33M USD
Operating income−135.81M USD−134.82M USD−93.46M USD−66.64M USD−48.64M USD
Net income−129.77M USD−127.5M USD−89.22M USD−66.22M USD−48.63M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-1
FY2025
Latest fiscal-year revenue
10.33M USD
FY2025 · +266.65% year over year
Next fiscal-year EPS consensus
-1.08
FY2026 · 4 analysts
Next fiscal-year revenue consensus
6.19M USD
FY2026 · 4 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-0.48-1.3-2.12-2.95FY21FY22FY23FY24FY25FY26FY27FY28

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend35.23M23.11M10.99M-1.14MFY21FY22FY23FY24FY25FY26FY27FY28

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$7.50

862.16% upside
Past 12 months12-month forecastHigh $12.00Average $7.50Low $3.00

Rating distribution

8 ratings
Strong buy00%
Buy788%
Hold113%
Sell00%
Strong sell00%

TCRX news

zacks.com

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.28 per share a year ago.

Read source
globenewswire.com

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process Cash and…

Read source
globenewswire.com

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies…

Read source
globenewswire.com

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

WALTHAM, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies…

Read source
globenewswire.com

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101

Read source
gurufocus.com

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology c

Read source

TCRX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding TCRX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.37M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
494.65K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
131.75K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research TCRX

research.disclaimer